We are excited to showcase our latest preclinical and translational oncology data and share how our services offer biotech and pharmaceutical companies the opportunity to remove the guesswork from their research and development. Schedule a meeting with our experts to discuss your needs further.
110 |
Developing Different Preclinical RAS Inhibitor Resistant Xenograft Models for Next-Generation Therapeutic EvaluationLocation: PB-110 |
217 |
Integrated Organoid Screening Approaches Enable Preclinical Assessment of Protein Degrader Efficacy and Target EngagementLocation: PB-112 |
261 |
Characterization of a Panel of PDX Models Derived from c-MET Targeting ADCs Pretreated Colorectal Cancer Patients for Therapeutic EvaluationLocation: PB-053 |
262 |
Establishing Preclinical Mouse Models for Translational Cancer Cachexia ResearchLocation: PB-054 |
343 |
Medicines Discovery Catapult (MDC) Colaboration:End-to-End In Vitro and In Vivo Evaluation of Radiopharmaceuticals in Patient-Derived ModelsLocation: PB-135 |
345 |
Benchmarking Multiple Comparison Procedures for Patient-Derived Xenograft Tumor-Volume StudiesLocation: PB-137 |
346 |
PDX-Derived Organoids Predict In Vivo Response Across KRAS Inhibitors and Antibody-Drug ConjugatesLocation: PB-138 |
Your privacy is important to us.
We'll never share your information.
2026-11-12
2026-10-19
landing_page
ENA 2026